Anti-EGFR Gamma Delta T-cell Engaging Bispecific Antibody SGN-EGFRd2

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A bispecific gamma delta T-cell engager (TCE) antibody targeting both the tumor-associated antigen (TAA) epidermal growth factor receptor (EGFR; HER1; ErbB1) and Vdelta2-T cell receptor (TCR) chain of Vgamma9Vdelta2 T-cells, with potential immunostimulating and antineoplastic activities. Upon administration, anti-EGFR gamma delta T-cell engaging bispecific antibody SGN-EGFRd2 binds to both EGFR-expressing tumor cells and Vgamma9Vdelta2 T-cells. This activates and redirects the Vgamma9Vdelta2 T-cells to EGFR-expressing tumor cells, and the Vgamma9Vdelta2 T-cells secrete interferon-gamma (IFN-g) and exert direct killing of tumor cells. In addition, the Vgamma9Vdelta2 T-cells activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against tumor cells. Gamma delta T-lymphocytes play a key role in the activation of the immune system and do not require major histocompatibility complex (MHC)-mediated antigen presentation to exert their cytotoxic effect. The Vdelta2 gamma delta T-cell subset is one of the two major gamma delta T-cell subsets that is almost exclusively paired with the Vgamma9 chain. EGFR, overexpressed by a variety of cancers, plays a key role in tumor cell proliferation and survival.

**Synonyms:** - Anti-EGFR Gamma Delta T-cell Engaging Bispecific Antibody LAVA-1223 - Anti-EGFR Gamma Delta TCE Bispecific Antibody SGN-EGFRd2 - EGFR-targeting Gammabody LAVA-1223 - LAVA 1223 - LAVA-1223 - LAVA1223 - SGN EGFRd2 - SGN-EGFRd2 - SGNEGFRd2